

HR 3005

Medical Testing Availability Act of 2013

Congress: 113 (2013–2015, Ended)

Chamber: House

Policy Area: Health

Introduced: Aug 2, 2013

Current Status: Referred to the Subcommittee on Health.

Latest Action: Referred to the Subcommittee on Health. (Aug 2, 2013)

Official Text: <https://www.congress.gov/bill/113th-congress/house-bill/3005>

Sponsor

Name: Rep. Burgess, Michael C. [R-TX-26]

Party: Republican • **State:** TX • **Chamber:** House

Cosponsors (7 total)

Cosponsor	Party / State	Role	Date Joined
Rep. Speier, Jackie [D-CA-14]	D · CA		Aug 2, 2013
Rep. Honda, Michael M. [D-CA-17]	D · CA		Sep 10, 2013
Rep. Eshoo, Anna G. [D-CA-18]	D · CA		Sep 18, 2013
Rep. Granger, Kay [R-TX-12]	R · TX		Sep 26, 2013
Rep. Higgins, Brian [D-NY-26]	D · NY		Sep 26, 2013
Rep. Brownley, Julia [D-CA-26]	D · CA		Oct 7, 2013
Rep. Peters, Scott H. [D-CA-52]	D · CA		Nov 18, 2013

Committee Activity

Committee	Chamber	Activity	Date
Energy and Commerce Committee	House	Referred to	Aug 2, 2013

Subjects & Policy Tags

Policy Area:

Health

Related Bills

No related bills are listed.

Medical Testing Availability Act of 2013 - Amends the Federal Food, Drug, and Cosmetic Act with respect to labeling in the shipment or delivery of an in vitro diagnostic product for an investigation exempt from compliance with a performance standard or the requirement of premarket approval.

Declares that such a product whose labeling states "*For Research Use Only. Not for use in diagnostic procedures.*" may not be deemed misbranded on the basis that its manufacturer or distributor: (1) sells the product to an end user who uses the product in a manner inconsistent with such statement, or (2) engages in business communications regarding the product with an end user.

Defines "business communications": (1) as oral, written, or electronic contact between a manufacturer or distributor of such a product and an end user regarding the product's functioning; and (2) includes any such contact consisting of technical support, customer service, assistance with the installation of such product, communication relating to ensuring the performance of the product, and other similar contacts.

Actions Timeline

- **Aug 2, 2013:** Introduced in House
- **Aug 2, 2013:** Referred to the House Committee on Energy and Commerce.
- **Aug 2, 2013:** Referred to the Subcommittee on Health.